Compare AMC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMC | DRUG |
|---|---|---|
| Founded | 1920 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 786.8M | 707.1M |
| IPO Year | 2007 | 2020 |
| Metric | AMC | DRUG |
|---|---|---|
| Price | $1.61 | $88.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $2.03 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 33.5M | 151.6K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,848,900,000.00 | N/A |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.57 | N/A |
| 52 Week Low | $0.93 | $23.18 |
| 52 Week High | $4.08 | $123.75 |
| Indicator | AMC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 59.33 |
| Support Level | $1.44 | $72.06 |
| Resistance Level | $1.79 | $91.69 |
| Average True Range (ATR) | 0.15 | 4.13 |
| MACD | 0.00 | 0.25 |
| Stochastic Oscillator | 49.23 | 69.87 |
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.